Rivoceranib (Apatinib) is a small molecule drug candidate which has been approved in China and has completed Phase 1/2A development in the US. It is being developed for the treatment of certain solid tumor cancers including Metastatic Gastric Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Metastatic Breast Cancer, and Non-Small Cell Lung Cancer.

Learn More About Rivoceranib

Bruton’s tyrosine kinase (BTK) and Janus kinase 3 (JAK3) dual targeting presents a unique opportunity for the effective treatment of both hematologic and autoimmune disorders. BTK targeting has been clinically validated for the treatment of hematologic malignances such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and for the treatment of autoimmune disorders such as rheumatoid arthritis.

Learn More About LSK9985